Dr. Sheppard’s Bio

Working within Medical Affairs, Dr. Sheppard is responsible for developing and maintaining KOL and External Expert relationships, supporting local patient organizations, delivering clinical presentations to payer audiences and supporting medical education initiatives. His current areas of focus include disease state education of Non-24 and its first and only FDA-approved treatment, Hetlioz, and Fanapt, an antipsychotic medication for the treatment of schizophrenia in adults. His territory encompasses the Northeastern United States.

Dr. Sheppard has spent the last decade working in the field of sleep medicine. He earned his PhD from the State University of New York at Albany, where he studied circadian rhythms, behavior, and sleep. Dr. Sheppard has held post-doctoral positions at the University of Notre Dame and the Florida State University*.*Most recently, as a Medical Science Liaison with Vanda Pharmaceuticals, he has been studying circadian rhythm disorders and educating health care providers and blindness organizations about Non-24.